Capstone Investment Advisors’s 10x Genomics TXG Stock Holding History

Capstone Investment Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$271K	Buy	+7,067	New	+$185K	﹤0.01%	1509
2025 Q4	–	Sell	-29,776	Closed	-$348K	–	2063
2025 Q3	$348K	Buy	+29,776	New	+$388K	﹤0.01%	1577
2024 Q3	–	Sell	-12,677	Closed	-$247K	–	2211
2024 Q2	$247K	Sell	12,677 -3,438	-21%	-$90K	﹤0.01%	1678
2024 Q1	$605K	Buy	16,115 +10,589	+192%	+$465K	﹤0.01%	1456
2023 Q4	$309K	Buy	+5,526	New	+$240K	﹤0.01%	1579

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capstone Investment Advisors's TXG Position: Q2 2026 in Review

Capstone Investment Advisors opened a new position in 10x Genomics (TXG) in Q2 2026: 7,067 shares worth $271K. The stake represents ﹤0.01% of the portfolio and ranks #1509 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in TXG as recently as Q3 2025.

Capstone Investment Advisors first reported a position in TXG in Q4 2023 and has held it in 5 quarters since. The position peaked at $605K in Q1 2024. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Capstone Investment Advisors held 7,067 shares of 10x Genomics worth $271K as of Q2 2026.
10x Genomics was a new Capstone Investment Advisors position in Q2 2026.
10x Genomics made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1509 holding.
Capstone Investment Advisors first reported a position in 10x Genomics in Q4 2023 and has held it in 5 quarters since.
Capstone Investment Advisors's 10x Genomics position peaked at $605K in Q1 2024.
393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.